$MMPR Announces Memorandum of Understanding With Broken Coast Cannabis Ltd

announces a Memorandum Of Understanding with Broken Coast Cannabis  (https://www.brokencoast.ca/) — a licensed Health Canada Medical Marijuana provider under MMPR guidelines (https://www.hc-sc.gc.ca/dhp-mps/marihuana/info/list-eng.php) and a company who also belongs to theCanadian Medical Cannabis Industry Association (https://www.cmcia.ca/ :https://www.cmcia.ca/broken-coast-cannabis-joins-the-cmcia/).

Easton Pharmaceuticals entered the lucrative Medical Marijuana cultivation and distribution industry via the acquisition of a grower and partnership with Medicated Markets International LLC, a California based medical marijuana grower (announced Dec 31, 2014). Easton has since been contacted by multiple currently licensed Canadian MMPR providers to explore synergies in the industry. As a result and following the efforts of Easton management and key consultants, the company is pleased to announce that Broken Coast and Easton Pharmaceuticals have agreed on an MOU. Details of the MOU are presently being withheld and will be released and highlighted in subsequent releases following the execution of a final agreement between “Broken Coast Cannabis” and Easton.

Broken Coast Cannabis, who have operations in British Columbia, Canada, with distribution capabilities to all of Canada as well as Washington State, have been in discussions with Easton Pharmaceuticals since January 2015. As a result of Easton’s recently executed agreement with Medicated Markets, it has allowed for synergies to develop in both the U.S. and Canadian markets. Those synergies are being explored and to be presented in the coming weeks.

Easton Pharmaceuticals and Medicated Markets Representatives are planning to visit Broken Coast Cannabis at their growing facility by the end of March 2015. Easton is attempting to furnish as much detail and transparency as can be provided and will provide further updates when currently discussed outstanding aspects of a final agreement are agreed to and executed.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their GroZone anti-microbial airflow system needed for growing pesticide free medicine, and currently have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
https://www.eastonpharmaceuticalsinc.com
https://ecigmarkets.com/
https://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.